Oppenheimer Cuts Chemed (NYSE:CHE) Price Target to $500.00

Chemed (NYSE:CHE) had its target price trimmed by Oppenheimer from $580.00 to $500.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, January 21st. Zacks Research upgraded Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th. Jefferies Financial Group downgraded Chemed from a “buy” rating to a “hold” rating in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $422.00 price objective (down from $572.00) on shares of Chemed in a research report on Friday. Two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $498.00.

Chemed Stock Performance

Shares of CHE opened at $410.14 on Friday. Chemed has a 52-week low of $385.00 and a 52-week high of $623.60. The firm has a market cap of $5.81 billion, a price-to-earnings ratio of 22.33, a PEG ratio of 1.52 and a beta of 0.47. The business’s fifty day moving average is $446.06 and its 200-day moving average is $443.85.

Chemed (NYSE:CHE) last released its quarterly earnings data on Wednesday, February 25th. The company reported $6.42 earnings per share for the quarter, missing the consensus estimate of $7.02 by ($0.60). The business had revenue of $639.34 million during the quarter, compared to analyst estimates of $659.09 million. Chemed had a net margin of 10.48% and a return on equity of 25.66%. The business’s quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the business earned $6.83 earnings per share. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. As a group, research analysts forecast that Chemed will post 21.43 EPS for the current fiscal year.

Chemed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 13th. Shareholders of record on Monday, February 23rd will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Monday, February 23rd. This represents a $2.40 annualized dividend and a yield of 0.6%. Chemed’s payout ratio is presently 13.06%.

Hedge Funds Weigh In On Chemed

A number of hedge funds have recently made changes to their positions in CHE. Commonwealth Equity Services LLC boosted its holdings in Chemed by 3.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 734 shares of the company’s stock valued at $314,000 after acquiring an additional 22 shares during the last quarter. WCM Investment Management LLC lifted its position in shares of Chemed by 3.8% in the 3rd quarter. WCM Investment Management LLC now owns 661 shares of the company’s stock worth $299,000 after purchasing an additional 24 shares during the period. Eukles Asset Management boosted its stake in shares of Chemed by 0.4% in the 3rd quarter. Eukles Asset Management now owns 6,031 shares of the company’s stock valued at $2,700,000 after purchasing an additional 24 shares during the last quarter. Cim LLC increased its position in shares of Chemed by 1.1% during the third quarter. Cim LLC now owns 2,139 shares of the company’s stock worth $958,000 after buying an additional 24 shares during the period. Finally, Atria Investments Inc increased its position in shares of Chemed by 0.6% during the second quarter. Atria Investments Inc now owns 4,259 shares of the company’s stock worth $2,074,000 after buying an additional 25 shares during the period. 95.85% of the stock is currently owned by institutional investors.

More Chemed News

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Oppenheimer lowered its price target but kept an “outperform” rating (PT cut to $500), signaling some analysts still see multi‑quarter upside despite the recent miss. Oppenheimer PT/Rating
• Neutral Sentiment: RBC reaffirmed a “sector perform” rating and set a $422 target (down from $572), reflecting a more cautious stance but not a full downgrade; this indicates mixed analyst conviction. RBC note
• Neutral Sentiment: Chemed issued FY‑2026 EPS guidance of $23.25–$24.25 (roughly in line but slightly below consensus), and said ~55% of 2026 earnings are likely back‑half weighted as it executes transition initiatives — guidance tempers but does not eliminate investor concern. Earnings release / guidance
• Neutral Sentiment: Full Q4 earnings and conference-call transcripts were posted (Seeking Alpha, Yahoo, others); these provide management commentary on margin compression, VITAS trends and cash‑flow dynamics for investors doing deeper diligence. Earnings call transcript
• Negative Sentiment: Zacks highlights the headline: Q4 EPS and revenue missed consensus, margins contracted and the FY‑2026 EPS outlook came in below street expectations — the earnings shock was the primary catalyst for the sharp share drop. Zacks: Earnings & margins miss
• Negative Sentiment: Detailed quarter metrics (QuiverQuant) show revenue and EPS declines, steeper drops in operating cash flow and lower cash balances — these raise near‑term liquidity and execution risk concerns for investors. QuiverQuant: Financial details
• Negative Sentiment: Johnson Fistel announced an investigation into possible claims tied to Chemed executives — potential litigation risk can amplify selling pressure and valuation uncertainty. GlobeNewswire: Investigation notice
• Negative Sentiment: BofA cut Chemed to neutral after the Q4 miss — another sign of weakening analyst conviction that can pressure sentiment until evidence of margin/cash‑flow stabilization appears. MSN / BofA note

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.